SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 21.23 |
Enterprise Value ($M) | 12.33 |
Book Value ($M) | 14.14 |
Book Value / Share | 0.84 |
Price / Book | 1.50 |
NCAV ($M) | -2.73 |
NCAV / Share | -0.16 |
Price / NCAV | -7.79 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.57 |
Return on Assets (ROA) | -0.32 |
Return on Equity (ROE) | -0.60 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.45 |
Current Ratio | 3.45 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 30.26 |
Assets | 47.13 |
Liabilities | 32.99 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Alyeska Investment Group, L.P. | 9.99 | -0.53 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
13,589 | 48,498 | 28.02 | |
20,812 | 55,572 | 37.45 | |
10,023 | 59,729 | 16.78 | |
14,243 | 95,977 | 14.84 | |
16,263 | 140,382 | 11.58 | |
(click for more detail) |
Similar Companies | |
---|---|
TWST – Twist Bioscience Corporation | TXMD – TherapeuticsMD, Inc. |
TYRA – Tyra Biosciences, Inc. | UTHR – United Therapeutics Corporation |
VERV – Verve Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io